<DOC>
	<DOCNO>NCT01205737</DOCNO>
	<brief_summary>This prospective international , multi-center , randomize , double-blind control study design ass compare pharmacokinetics , pharmacodynamics safety MabThera® TL011 , combination CHOP previously untreated patient diffuse large B cell lymphoma .</brief_summary>
	<brief_title>A Double-blind , Randomized Controlled Study CD20-positive Diffuse B Cell Non-Hodgkin 's Lymphoma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>Newly diagnose subject confirm pathologic diagnosis diffuse large B cell nonHodgkin 's lymphoma ( DLBCL ) base 2008 World Health Organization classification . 2.CD20+ lymphoma cell screen 1880 ( inclusive ) year age screen Ann Arbor Stages IIV screen Any IPI score screen ECOG good performance status ( 02 ) screen Willing able provide write informed consent prior perform study procedure Women childbearing potential must use effective contraceptive method start screen 12 month follow last infusion.. 1 . Any lymphoma CD20+ DLBCL 2 . History indolent lymphoma 3 . DLBCL central nervous system meningeal involvement 4 . Primary gastrointestinal ( MALT ) lymphoma 5 . Bulky disease &gt; 10 cm diagnose image screen 6 . Bone marrow involvement &gt; 25 % accord bone marrow biopsy screen 7 . Subjects previously treat chemotherapy , radiotherapy , immunotherapy experimental therapy lymphoma malignancy 8 . Hypersensitivity active ingredient , excipients ( sodium citrate , polysorbate 80 , sodium chloride , sodium hydroxide , hydrochloric acid , water injection ) murine proteins 9 . Active uncontrolled infection ( viral , bacterial fungal infection ) require systemic therapy screen and/or baseline visit . 10 . A documented history recurrent chronic clinically significant infection ( viral , bacterial fungal infection ) 11 . Subjects history tuberculosis active tuberculosis screening . 12 . Immunodeficiency syndrome Human immunodeficiency virus ( HIV ) seropositivity 13 . Positive Hepatitis B surface antigen antibody Hepatitis C 14 . History cancer within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma uterine cervix 15 . Any major surgical procedure within 12 week prior screen screen baseline 16 . Immunization live viral vaccine less 4 week prior first study drug infusion , and/or plan live viral vaccination study period . 17 . Known allergic reaction foreign proteins 18 . Subjects 8 cycle CHOP might problematic , follow findings/conditions , enrol : Cardiac contraindication doxorubicin : Left ventricular ejection fraction ( LVEF ) &lt; 50 % accord multiacquisition gate ( MUGA ) scan 2D Echocardiogram screen Neurologic contraindication vincristine : ( e.g. , peripheral neuropathy ) Abnormal hepatic function screen and/or baseline AST/ALT ≥ 3 x upper normal value ( ULN ) ≥ 5 x ULN presence DLBCL involvement liver Bilirubin ≥ 2 x ULN ≥ 5 x ULN presence DLBCL involvement liver Abnormal renal function screen and/or baseline Serum creatinine ≥ 2 x ULN Abnormal bone marrow function screen and/or baseline Platelets &lt; 100x109/L Neutrophils &lt; 1.5x109/L Hb &lt; 9g/dL 19 . Any serious active disease comorbid medical condition ( accord investigator 's decision information provide Investigator Brochure TL011 ) 20 . Subjects , accord investigator , likely noncompliant uncooperative study . 21 . Pregnant lactate woman woman intend get pregnant study within 12 month follow last infusion . 22 . Treatment investigational drug within 90 day plan first cycle chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>